UNSPSC 51422344: Dexamethasone trimethyl acetate

This classification denotes a therapeutic glucocorticoid and antiemetic agent with the molecular formula C27H37FO6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K182597N9C, chemically known as pregna-1,4-diene-3,20-dione, 21-(2,2-dimethyl-1-oxopropoxy)-9-fluoro-11,17-dihydroxy-16-methyl-, (11.beta.,16.alpha.)-, but more generally known as dexamethasone trimethyl acetate, which bears US NIH Compound Identifier 63040.

European Medicines Agency schedules dexamethasone trimethyl acetate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07017MIG. Most nations, for tariff purposes, schedule dexamethasone trimethyl acetate under HS 29372200. SMILES: C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)COC(=O)C(C)(C)C)O)C)O)F)C.

UNSPSC 51422344 Dexamethasone trimethyl acetate is a Commodity code, but the recent state and local opportunities posted under it show little relevance to the nominal pharmaceutical active ingredient — the two solicitations on file are for naloxone and drug deactivation systems (Seminole County, Florida) and a Request for Information on direct-to-manufacturer pharmacy programs (Texas Health and Human Services Commission), neither of which concerns dexamethasone trimethyl acetate specifically. The code assignment appears to be a mismatch between the abstract pharmaceutical classification and the work actually being solicited at the state and local level.

The geographic activity that does appear under this code reflects preliminary procurement exploration rather than active contracting. Seminole County's IFB60459723LAS, posted June 30, 2026, seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, with a response deadline of July 26, 2026, under a two-year initial term plus one-year renewal option. The Texas HHS Commission's RFI HHS0017013, posted April 3, 2026, is an information-gathering exercise on direct-to-manufacturer prescription delivery models for state pharmacy benefit programs, with no formal award value or timeline specified. Until state and local procurement offices begin tagging active dexamethasone trimethyl acetate opportunities under this code, the code shows no substantive market signal for business development purposes.